Tekmira Pharmaceuticals Corp. - Product Pipeline Review - 2015

Published: Jun, 2015 | Pages: 71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Tekmira Pharmaceuticals Corp. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Tekmira Pharmaceuticals Corp. - Product Pipeline Review - 2015', provides an overview of the Tekmira Pharmaceuticals Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Tekmira Pharmaceuticals Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Tekmira Pharmaceuticals Corp. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Tekmira Pharmaceuticals Corp.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Tekmira Pharmaceuticals Corp.'s pipeline products

Reasons to buy

- Evaluate Tekmira Pharmaceuticals Corp.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Tekmira Pharmaceuticals Corp. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Tekmira Pharmaceuticals Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Tekmira Pharmaceuticals Corp. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Tekmira Pharmaceuticals Corp.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Tekmira Pharmaceuticals Corp. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Tekmira Pharmaceuticals Corp. Snapshot 6
Tekmira Pharmaceuticals Corp. Overview 6
Key Information 6
Key Facts 6
Tekmira Pharmaceuticals Corp. - Research and Development Overview 7
Key Therapeutic Areas 7
Tekmira Pharmaceuticals Corp. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
Tekmira Pharmaceuticals Corp. - Pipeline Products Glance 16
Tekmira Pharmaceuticals Corp. - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Tekmira Pharmaceuticals Corp. - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Tekmira Pharmaceuticals Corp. - Drug Profiles 20
TKM-Ebola-Guinea 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
TKM-PLK1 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
TKM-100802 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
TKMHBV-1 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
TKMHBV-2 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
CCC-0346 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
CCC-0975 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CYT-003-QbG10 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecule to Inhibit HBsAg for Hepatitis B 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
NVP-018 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
RNAi Oligonucleotide to Inhibit CSN5 for Hepatocellular Carcinoma 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
RNAi Oligonucleotide to Inhibit WEE1 for Hepatocellular Carcinoma 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
TKM-ALDH2 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
TKM-GSD 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
TKM-HTG 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
TKM-Marburg 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
TKMApoC-3 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
DVR-23 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecules for Dengue 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecules for Hepatitis B Infections 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecules to Agonize Sting Receptor for Hepatitis B 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Tekmira Pharmaceuticals Corp. - Pipeline Analysis 50
Tekmira Pharmaceuticals Corp. - Pipeline Products by Target 50
Tekmira Pharmaceuticals Corp. - Pipeline Products by Route of Administration 51
Tekmira Pharmaceuticals Corp. - Pipeline Products by Molecule Type 52
Tekmira Pharmaceuticals Corp. - Pipeline Products by Mechanism of Action 53
Tekmira Pharmaceuticals Corp. - Recent Pipeline Updates 54
Tekmira Pharmaceuticals Corp. - Dormant Projects 64
Tekmira Pharmaceuticals Corp. - Company Statement 65
Tekmira Pharmaceuticals Corp. - Locations And Subsidiaries 69
Head Office 69
Other Locations & Subsidiaries 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables

Tekmira Pharmaceuticals Corp., Key Information 6
Tekmira Pharmaceuticals Corp., Key Facts 6
Tekmira Pharmaceuticals Corp. - Pipeline by Indication, 2015 8
Tekmira Pharmaceuticals Corp. - Pipeline by Stage of Development, 2015 10
Tekmira Pharmaceuticals Corp. - Monotherapy Products in Pipeline, 2015 11
Tekmira Pharmaceuticals Corp. - Partnered Products in Pipeline, 2015 12
Tekmira Pharmaceuticals Corp. - Partnered Products/ Combination Treatment Modalities, 2015 13
Tekmira Pharmaceuticals Corp. - Out-Licensed Products in Pipeline, 2015 14
Tekmira Pharmaceuticals Corp. - Out-Licensed Products/ Combination Treatment Modalities, 2015 15
Tekmira Pharmaceuticals Corp. - Phase II, 2015 16
Tekmira Pharmaceuticals Corp. - Phase I, 2015 17
Tekmira Pharmaceuticals Corp. - Preclinical, 2015 18
Tekmira Pharmaceuticals Corp. - Discovery, 2015 19
Tekmira Pharmaceuticals Corp. - Pipeline by Target, 2015 50
Tekmira Pharmaceuticals Corp. - Pipeline by Route of Administration, 2015 51
Tekmira Pharmaceuticals Corp. - Pipeline by Molecule Type, 2015 52
Tekmira Pharmaceuticals Corp. - Pipeline Products by Mechanism of Action, 2015 53
Tekmira Pharmaceuticals Corp. - Recent Pipeline Updates, 2015 54
Tekmira Pharmaceuticals Corp. - Dormant Developmental Projects,2015 64
Tekmira Pharmaceuticals Corp., Subsidiaries 69